OtherPerspective

Recent research hotspots in sequencing and the pancreatic neuroendocrine tumor microenvironment

Junfeng Xu, Wuhu Zhang, Xin Lou, Zeng Ye, Yi Qin, Jie Chen, Xiaowu Xu, Xianjun Yu and Shunrong Ji
Cancer Biology & Medicine October 2023, 20 (10) 721-727; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0284

References

  1. 1.↵
    2. Xu J,
    3. Ye Z,
    4. Zhuo Q,
    5. Gao H,
    6. Qin Y,
    7. Lou X, et al.
    MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression. Cancer Res. 2023; 83: 2226–47.
    OpenUrl
  2. 2.↵
    2. Li H,
    3. Liu H,
    4. Chen K.
    Living biobank-based cancer organoids: prospects and challenges in cancer research. Cancer Biol Med. 2022; 19: 965–82.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Zhang WH,
    3. Xu JF,
    4. Hu YH,
    5. Qin Y,
    6. Chen J,
    7. Yu XJ, et al.
    The surgical and therapeutic activities of non-functional pancreatic neuroendocrine tumors at a high-volume institution. Cancers (Basel). 2023; 15: 1955.
    OpenUrl
  4. 4.↵
    2. Jiang R,
    3. Hong X,
    4. Zhao Y,
    5. Wu W.
    Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett. 2021; 499: 39–48.
    OpenUrl
  5. 5.↵
    2. Ji SR,
    3. Xu XW,
    4. Yu XJ.
    Advances in basic and translational research in neuroendocrine neoplasms. Zhonghua Wei Chang Wai Ke Za Zhi. 2021; 24: 867–74.
    OpenUrl
  6. 6.↵
    2. Bai R,
    3. Li W,
    4. Cui J.
    Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. Cancer Biol Med. 2022; 19: 1649–61.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Cao Y,
    3. Gao Z,
    4. Li L,
    5. Jiang X,
    6. Shan A,
    7. Cai J, et al.
    Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun. 2013; 4: 2810.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Keutgen XM,
    3. Kumar S,
    4. Gara SK,
    5. Boufraqech M,
    6. Agarwal S,
    7. Hruban RH, et al.
    Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype. Cancer. 2018; 124: 636–47.
    OpenUrl
  9. 9.↵
    2. Xiao Y,
    3. Yu TJ,
    4. Xu Y,
    5. Ding R,
    6. Wang YP,
    7. Jiang YZ, et al.
    Emerging therapies in cancer metabolism. Cell Metab. 2023; 35: 1283–303.
    OpenUrl
  10. 10.↵
    2. Ma Y,
    3. Zhu Q,
    4. Wang X,
    5. Liu M,
    6. Chen Q,
    7. Jiang L, et al.
    Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Res. 2022; 32: 596–9.
    OpenUrl
  11. 11.↵
    2. Ye Z,
    3. Chen H,
    4. Ji S,
    5. Hu Y,
    6. Lou X,
    7. Zhang W, et al.
    MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. Acta Biochim Biophys Sin (Shanghai). 2022; 54: 1599–609.
    OpenUrl
  12. 12.↵
    2. Hong X,
    3. Qiao S,
    4. Li F,
    5. Wang W,
    6. Jiang R,
    7. Wu H, et al.
    Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut. 2020; 69: 877–87.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Mo S,
    3. Zong L,
    4. Chen X,
    5. Chang X,
    6. Lu Z,
    7. Yu S, et al.
    High mast cell density predicts a favorable prognosis in patients with pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2022; 112: 845–55.
    OpenUrl
  14. 14.↵
    2. Jacenik D,
    3. Lebish EJ,
    4. Beswick EJ.
    MK2 promotes the development and progression of pancreatic neuroendocrine tumors mediated by macrophages and metabolomic factors. Int J Mol Sci. 2022; 23: 13561.
  15. 15.↵
    2. Zhang WH,
    3. Wang WQ,
    4. Han X,
    5. Gao HL,
    6. Xu SS,
    7. Li S, et al.
    Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer. 2020; 8: e001188.
  16. 16.↵
    2. Wei M,
    3. Xu J,
    4. Hua J,
    5. Meng Q,
    6. Liang C,
    7. Liu J, et al.
    From the immune profile to the immunoscore: Signatures for improving postsurgical prognostic prediction of pancreatic neuroendocrine tumors. Front Immunol. 2021; 12: 654660.
  17. 17.↵
    2. Beauchamp RD,
    3. Coffey RJ, Jr.,
    4. Lyons RM,
    5. Perkett EA,
    6. Townsend CM, Jr.,
    7. Moses HL.
    Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res. 1991; 51: 5253–60.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Wimmel A,
    3. Wiedenmann B,
    4. Rosewicz S.
    Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumour cells. Gut. 2003; 52: 1308–16.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    2. Cuny T,
    3. de Herder W,
    4. Barlier A,
    5. Hofland LJ.
    Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocr Relat Cancer. 2018; 25: R519–44.
    OpenUrl
  20. 20.↵
    2. Lou X,
    3. Qin Y,
    4. Xu X,
    5. Yu X,
    6. Ji S.
    Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors. Biochim Biophys Acta Rev Cancer. 2022; 1877: 188782.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section